Xenon Pharmaceuticals Inc.
XENE
Classificação em ações
#4534
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Preço da ação
$34.95
Valor de mercado
$3.38B
Variação (1 dia)
4.36%
Variação (1 ano)
-16.05%
País
CA
Negociar Xenon Pharmaceuticals Inc. (XENE)
Categoria
Healthcare
EPS de Xenon Pharmaceuticals Inc. (XENE)
EPS em June 2026 TTM: $-4.74
De acordo com os últimos relatórios financeiros e o preço das ações da Xenon Pharmaceuticals Inc., o EPS atual da empresa (TTM) é $-4.74. No final de 2023, a empresa teve um EPS de $-2.73, um aumento em relação a ao EPS de 2022, que foi de $-2.06.
Histórico de EPS da Xenon Pharmaceuticals Inc. de 2011 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-4.74 | 57.48% |
| 2024 | $-3.01 | 10.26% |
| 2023 | $-2.73 | 32.52% |
| 2022 | $-2.06 | 16.38% |
| 2021 | $-1.77 | 113.25% |
| 2020 | $-0.83 | -46.10% |
| 2019 | $-1.54 | -13.48% |
| 2018 | $-1.78 | 4.09% |
| 2017 | $-1.71 | 15.54% |
| 2016 | $-1.48 | 34.55% |
| 2015 | $-1.10 | -217.02% |
| 2014 | $0.94 | 123.81% |
| 2013 | $0.42 | -113.00% |
| 2012 | $-3.23 | -64.19% |
| 2011 | $-9.02 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | -465.40% |
US
|
|
| $-7.98 | 68.35% |
US
|
|
| $-5.29 | 11.60% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -685.23% |
NL
|
